Drug intelligence / Profile preview

BCI-1229

Development stage: Preclinical
Lead developer: Gedeon Richter
Modality: Small Molecules

Overview

BCI-1229 is a small molecule inhibitor of colony-stimulating factor 1 receptor (CSF1R) developed by BCI Pharma. It is being investigated for the treatment of acute myeloid leukemia (AML). BCI-1229 targets CSF1R to block infiltrating monocytes and tumor-associated macrophages in the bone marrow stroma, thereby disrupting the supportive tumor microenvironment that contributes to disease development and therapy resistance. In preclinical studies, BCI-1229 has demonstrated potent inhibition of CSF1R-dependent cell lines, showing greater potency than the reference inhibitor BLZ-945.

Targets

CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on BCI-1229.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCI-1229.